Amycretin trial results lift Novo shares

Zealand Pharma A/S

25/11/2025 12:10

** Shares in Novo Nordisk NOVOb.CO rise nearly 4% after its amycretin study showed significant weight loss and reduction in blood sugar (HbA1c) in type 2 diabetes

** Amycretin showed statistically significant weight loss of up to 14.5% at 36 weeks in phase 2 trial, the drugmaker said in a statement

** It also demonstrated statistically significant reductions in HbA(1c) with up to 89.1% achieving HbA(1c) levels below 7%

** Amycretin, Novo's next-generation obesity drug, mimics the gut hormone GLP-1 like Wegovy and also copies the hunger-suppressing effect of the pancreatic hormone amylin

** Novo added it plans to initiate a phase 3 for amycretin in 2026

** Novo Nordisk share is among top risers on the pan-European STOXX 600 .STOXX index

** Shares of local peer Zealand Pharma ZELA.CO are down 5%

 (Reporting by Elviira Luoma)

 ((Elviira.luoma@thomsonreuters.com))